ストックスクリーナーアプリを入手
21.35
7.97%
-1.85
アフターアワーズ：
21.35
Arcus Biosciences Inc (RCUS) 最新ニュース
Can Arcus Biosciences Inc. stock double in next 5 yearsMarket Performance Recap & AI Enhanced Trade Execution Alerts - ulpravda.ru
Arcus Biosciences (RCUS) Downgraded by Morgan Stanley Amid Recen - GuruFocus
Will Arcus Biosciences Inc. stock maintain growth storyJuly 2025 Earnings & Accurate Buy Signal Alerts - ulpravda.ru
Arcus stock downgraded at Morgan Stanley (RCUS:NYSE) - Seeking Alpha
Morgan Stanley Downgrades Arcus Biosciences (RCUS), Adjusts Pric - GuruFocus
Morgan Stanley downgrades Arcus Biosciences stock on balanced risk/reward - Investing.com Canada
Arcus Biosciences (RCUS) Sets Ambitious 2026 Agenda for Casdatif - GuruFocus
Biotech outlines 2026 plans for kidney cancer and atopic dermatitis - Stock Titan
Arcus Biosciences (RCUS) Shares Fall by Over 9% - GuruFocus
Arcus Biosciences (NYSE:RCUS) Trading Down 7.8% Following Insider Selling - MarketBeat
Portfolio Shifts: Is Arcus Biosciences Inc stock a buy for dividend growthLong Setup & AI Powered Buy and Sell Recommendations - moha.gov.vn
Insider Sell: Goeltz II Robert C. Sells Shares of Arcus Bioscien - GuruFocus
Insider Selling: Arcus Biosciences (NYSE:RCUS) CFO Sells 6,552 Shares of Stock - MarketBeat
The Technical Signals Behind (RCUS) That Institutions Follow - Stock Traders Daily
Arcus Biosciences (NYSE:RCUS) Trading Up 2.8%Should You Buy? - MarketBeat
Certain Common Stock of Arcus Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 30-DEC-2025. - marketscreener.com
Certain Stock Optios of Arcus Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 30-DEC-2025. - marketscreener.com
Certain Restricted Stock Units of Arcus Biosciences, Inc. are subject to a Lock-Up Agreement Ending on 30-DEC-2025. - MarketScreener
Is Arcus Biosciences Inc a good long term investmentDebt-to-Equity Ratio Analysis & AI-Based Predictions Available Free - earlytimes.in
Arcus Biosciences Earnings Notes - Trefis
Understanding Momentum Shifts in (RCUS) - news.stocktradersdaily.com
Can Arcus Biosciences Inc. stock deliver consistent earnings growthQuarterly Investment Review & Comprehensive Market Scan Reports - Улправда
Have Insiders Sold Arcus Biosciences Shares Recently? - simplywall.st
Squarepoint Ops LLC Boosts Stake in Arcus Biosciences, Inc. $RCUS - MarketBeat
Can Arcus Biosciences Inc. stock deliver sustainable ROEMarket Sentiment Report & Technical Confirmation Trade Alerts - Улправда
How higher bond yields impact Arcus Biosciences Inc. stockJuly 2025 Breakouts & Safe Entry Trade Signal Reports - ulpravda.ru
Is Arcus Biosciences Inc. stock attractive after correctionEarnings Growth Summary & Weekly Stock Performance Updates - Bölüm Sonu Canavarı
Market Outlook: Can Arcus Biosciences Inc. stock maintain operating marginsQuarterly Market Summary & Daily Entry Point Trade Alerts - DonanımHaber
Arcus Biosciences (NYSE:RCUS) Insider Richard Markus Sells 4,494 Shares - MarketBeat
Insider Selling: Arcus Biosciences (NYSE:RCUS) CAO Sells 4,343 Shares of Stock - MarketBeat
Carolyn Tang Sells 7,658 Shares of Arcus Biosciences (NYSE:RCUS) Stock - MarketBeat
Arcus Biosciences (NYSE:RCUS) President Sells $245,603.00 in Stock - MarketBeat
Robert Goeltz II Sells 6,702 Shares of Arcus Biosciences (NYSE:RCUS) Stock - MarketBeat
Arcus Biosciences (NYSE:RCUS) CEO Sells $633,360.36 in Stock - MarketBeat
Arcus Biosciences (NYSE:RCUS) General Counsel Sells $150,909.60 in Stock - MarketBeat
Arcus Biosciences amends loan agreement, extends maturity and updates terms - Investing.com Nigeria
Arcus Biosciences Insider Sold Shares Worth $466,870, According to a Recent SEC Filing - marketscreener.com
Arcus Biosciences Insider Sold Shares Worth $278,739, According to a Recent SEC Filing - marketscreener.com
Arcus Biosciences Insider Sold Shares Worth $318,496, According to a Recent SEC Filing - marketscreener.com
Arcus Biosciences Executives Sell Shares to Cover Tax Obligations - TradingView — Track All Markets
Officer Azoy Sells 4,343 ($96.6K) Of Arcus Biosciences Inc [RCUS] - TradingView — Track All Markets
[Form 4] Arcus Biosciences, Inc. Insider Trading Activity - Stock Titan
Arcus Biosciences Amends Loan Facility, Extends Maturity Terms - TipRanks
Arcus Biosciences to Participate in the 44th Annual J.P. Morgan Healthcare Conference - marketscreener.com
Cancer-focused Arcus Biosciences to present at major health conference - Stock Titan
February 2026 Options Now Available For Arcus Biosciences (RCUS) - Nasdaq
This growth stock with 137% upside faces new challenge: Buy, hold or sell? - MSN
Arcus Biosciences: Casdatifan Takes Center Stage After STAR-221 (NYSE:RCUS) - Seeking Alpha
Palmetto Grain Brokerage - Palmetto Grain Brokerage
This Growth Stock With 137% Upside Faces New Challenge: Buy, Hold or Sell? - Barchart.com
Officer Markus Files To Sell 10,000 Of Arcus Biosciences Inc [RCUS] - TradingView — Track All Markets
Pres Jaen Files To Sell 22,000 Of Arcus Biosciences Inc [RCUS] - TradingView — Track All Markets
Arcus Biosciences (NYSE: RCUS) shareholder files Rule 144 to sell 5,000 shares - Stock Titan
RCUS Stock Down on Decision to Discontinue GILD Partnered Study - Finviz
Arcus Biosciences stock price target raised to $32 at H.C. Wainwright - Investing.com Canada
Domvanalimab failure bad news for Arcus and TIGIT class - The Pharma Letter
Arcus Biosciences, Inc. (NYSE:RCUS) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Assessing Arcus Biosciences’ Valuation After Halting Key GI Trials and Pivoting to Casdatifan-Focused Strategy - simplywall.st
Gilead and Arcus halt late-stage study for anti-TIGIT cancer drug - MSN
Arcus Biosciences (RCUS) Stock News, Forecasts and Analyst Targets — Dec. 14, 2025 Update - ts2.tech
Why Arcus Biosciences (RCUS) Is Down 15.4% After Halting Key Domvanalimab Cancer Trials And What's Next - Yahoo Finance
Arcus Biosciences (NYSE:RCUS) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
0.80%
4.56%
大文字化:
|
ボリューム (24 時間):